Solithromycin treatment: Non inferior to moxifloxacin for pneumonia
Results in a clinical phase III shows that a 5-day regimen of oral solithromycin may be clinically non inferior to a 7-day regimen of oral moxifloxacin for the treatment of community-acquired bacterial pneumonia. Solithromycin, a next-generation macrolide, has a similar safety profile to moxifloxacin and could offer providers an alternative to the β-lactam and fluoroquinolone-based treatments. It is important that an effective, single-dose, oral treatment such as solithromycin to be taken so as to protect population that are at risk of contracting both gonococcus and chlamydia. References: http://www.healio.com/infectious-disease/respiratory-infections/news/online/%7Bcf4cf6fd-b59f-41bf-ab89-af93067421e3%7D/oral-solithromycin-noninferior-to-oral-moxifloxacin-for-pneumonia